CAJ | 학술논문

目的：探讨辛伐他汀对哮喘急性发作患者血清转化生长因子β1（TGF-β1）和白介素17（IL-17）水平的影响，为哮喘的临床防治提供新的治疗选择。方法选择2009年4月—2013年7月在中国石油大学（华东）医院内科住院的哮喘急性发作患者83例，随机分为常规治疗组43例和辛伐他汀组40例。两组患者均给予基础治疗，辛伐他汀组患者在此基础上加用辛伐他汀，均连续治疗7d。两组患者于治疗前及治疗后第8天进行哮喘控制测试（ ACT）评分，检测肺功能〔第一秒用力呼气容积占预计值百分比（ FEV1%）、第一秒用力呼吸容积占用力肺活量百分比（ FEV1/FVC）〕及血清TGF-β1和IL-17水平，记录辛伐他汀组患者治疗期间不良反应发生情况。结果治疗前后两组患者ACT评分、FEV1%及FEV1/FVC比较，差异均无统计学意义（ P>0.05）。治疗前两组患者血清TGF-β1、IL-17水平比较，差异无统计学意义（ P>0.05）；治疗后辛伐他汀组患者血清TGF-β1、IL-17水平低于对照组（ P
목적：탐토신벌타정대효천급성발작환자혈청전화생장인자β1（TGF-β1）화백개소17（IL-17）수평적영향，위효천적림상방치제공신적치료선택。방법선택2009년4월—2013년7월재중국석유대학（화동）의원내과주원적효천급성발작환자83례，수궤분위상규치료조43례화신벌타정조40례。량조환자균급여기출치료，신벌타정조환자재차기출상가용신벌타정，균련속치료7d。량조환자우치료전급치료후제8천진행효천공제측시（ ACT）평분，검측폐공능〔제일초용력호기용적점예계치백분비（ FEV1%）、제일초용력호흡용적점용력폐활량백분비（ FEV1/FVC）〕급혈청TGF-β1화IL-17수평，기록신벌타정조환자치료기간불량반응발생정황。결과치료전후량조환자ACT평분、FEV1%급FEV1/FVC비교，차이균무통계학의의（ P>0.05）。치료전량조환자혈청TGF-β1、IL-17수평비교，차이무통계학의의（ P>0.05）；치료후신벌타정조환자혈청TGF-β1、IL-17수평저우대조조（ P
Objective To explore the impact of simvastatin on serum levels of TGF-β1 and IL-17 of patients with acute asthma,to provide new therapeutic options for asthma. Methods From April 2009 to July 2013,a total of 83 in -patients with acute asthma were selected in the Department of Internal Medicine,China University of Petroleum( Huadong) Hospital,and they were randomly divided into control group(n=43)and observation group(n=40). Patients of both groups were given basic treatment,and patients of observation group were given extra simvastatin for 7 days. ACT score,lung function index including FEV1% and FEV1/FVC,serum levels of TGF-β1 and IL-17 were compared between the two groups before treatment and on the eighth day of treatment,and the incidence of adverse reactions of observation group was recorded during treatment. Results No statistically significant differences of ACT score, FEV1% or FEV1/FVC was found between the two groups before or after treatment(P>0. 05). No statistically significant differences of serum TGF-β1 or IL-17 level was found between the two groups before treatment ( P >0. 05 );while serum levels of TGF-β1 and IL-17 of observation group were statistically significantly lower than those of control group(P<0. 05). In observation group,3 cases occurred mild abdominal pain,constipation or flatulence, without affecting the treatment. Conclusion Simvastatin can effectively reduce the serum levels of TGF-β1 and IL -17,relieve the airway inflammatory reaction and delay process of airway remodeling,has certain therapeutic effect on acute asthma.